Hims & Hers adds unapproved compounded peptide treatments
CNBC · RSS · · AI-summarised by FinFlash
Hims & Hers is now offering compounded sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine through its telehealth platform, none of which are approved by the FDA. The company acknowledged there is more to learn about efficacy. The launch expands its cash-pay treatment menu into unapproved peptides, a regulatory risk investors should weigh against potential revenue growth.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.